Table 2.
Clinical Outcomes According to Vaccination Status and Anti-RBD IgG Level
| Outcome | Anti-RBD <500 AU/mL (N=14) | Anti-RBD >500 AU/mL (N=12) | P-value |
|---|---|---|---|
| Mortality | 2 (14.3%) | 2 (16.7%) | 1.00 |
| MACE | 3 (21.4%) | 3 (25.0%) | 1.00 |
| DVT/PE | 0 | 1 (8.3) | 0.46 |
| ICU admission | 2 (14.3%) | 1 (8.3%) | 1.00 |
| Need for mechanical ventilation | 2 (14.3%) | 1 (8.3%) | 1.00 |
| Need for supplemental oxygen | 12 (85.7%) | 7 (58.3%) | 0.26 |
| FIO2 needs (%) | 37 (30, 100) | 32 (21, 39) | 0.14 |
| Onset of symptoms prior to presentation (Days) | 6 (4, 9) | 5 (4, 6) | 0.92 |
| Overall LOS (Days) | 10 (6, 11) | 5 (3, 9) | 0.046* |
| Unvaccinated (N=13) | Vaccinated (N=13) | ||
| Anti-RBD Ab positive | 6 (46.2%) | 13 (100%) | 0.0052* |
| Anti-RBD titer (AU/mL) | 0 (0, 416) | 623 (298, 1345) | 0.011* |
| Anti-nucleocapsid Ab positive | 7 (53.9%) | 1 (7.7%) | 0.03* |
| Mortality | 2 (15.4%) | 2 (15.2%) | 1.00 |
| MACE | 2 (15.4%) | 4 (30.8%) | 0.64 |
| DVT/PE | 1 (7.7%) | 0 | 1.00 |
| ICU admission | 2 (15.4) | 1 (7.7) | 1.00 |
| Need for mechanical ventilation | 2 (15.4%) | 1 (7.7%) | 1.00 |
| Need for supplemental oxygen | 11 (84.6%) | 8 (61.5%) | 0.376 |
| Onset of symptoms prior to presentation (Days) | 8 (6, 8) | 4 (3, 4) | 0.006* |
| FIO2 needs (%) | 37 (37, 100) | 31 (21, 45) | 0.08 |
| Overall LOS (Days) | 9 (4, 11) | 8 (4, 9) | 0.45 |
Note: *Denotes significant p-value.